Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Trehalose API

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Seelos doses first subject in ALS basket trial in Australia
    Seelos doses first subject in ALS basket trial in Australia

    19 Jul 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/seelo-amyotrophic-lateral-sclerosis-study/

    CLINICALTRIALSARENA
    19 Jul 2022
    Share Share
    Seelos Receives FDA May Proceed Notice to Initiate a Ph IIb/III Trial SLS-005
    Seelos Receives FDA May Proceed Notice to Initiate a Ph IIb/III Trial SLS-005

    10 Aug 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/seelos-therapeutics-receives-fda-may-proceed-notice-to-initiate-a-phase-iibiii-trial-of-sls-005-in-amyotrophic-lateral-sclerosis-301108763.html#:~:text=Men's%20Interest-,Seelos%20Therapeutics%20Receives%20FDA%20May%20Proceed%20Notice%20to%20Initiate%20a,005%20in%20Amyotrophic%20Lateral%20Sclerosis&text=Seelos%20Therapeutics%2C%20Inc.&text=These%20mutations%20contribute%20to%20the,as%20TDP%2D43%20and%20SOD1.

    PRNEWSWIRE
    10 Aug 2020
    Share Share
    Seelos Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005
    Seelos Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005

    21 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/seelos-therapeutics-receives-positive-ema-opinion-on-orphan-drug-designation-for-sls-005-trehalose-in-sanfilippo-syndrome-301096451.html

    PRNEWSWIRE
    21 Jul 2020
    Share Share
    Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics
    Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics

    19 Feb 2019

    // PRESS RELEASE

    https://ir.bioblastpharma.com/news-releases/news-release-details/bioblast-pharma-announces-sale-its-trehalose-clinical

    PRESS RELEASE
    19 Feb 2019
    Share Share
    Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma
    Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

    19 Feb 2019

    // GLOBNEWSWIRE

    https://globenewswire.com/news-release/2019/02/19/1734213/0/en/Seelos-Therapeutics-Completes-Acquisition-of-Trehalose-from-Bioblast-Pharma.html

    GLOBNEWSWIRE
    19 Feb 2019
    Share Share
    Bioblast Pharma Collaborates to Evaluate Trehalose for Sanfilippo Syndrome
    Bioblast Pharma Collaborates to Evaluate Trehalose for Sanfilippo Syndrome

    14 Feb 2019

    // NASDAQ

    https://www.nasdaq.com/press-release/bioblast-pharma-announces-collaboration-with-team-sanfilippo-to-evaluate-trehalose--for-the--20190214-01371

    NASDAQ
    14 Feb 2019
    Share Share